miRacle of microRNA-Driven Cancer Nanotherapeutics

Goknur Kara, Banu Arun, George A. Calin, Bulent Ozpolat

Research output: Contribution to journalReview articlepeer-review


MicroRNAs (miRNAs) are non-protein-coding RNA molecules 20–25 nucleotides in length that can suppress the expression of genes involved in numerous physiological processes in cells. Accumulating evidence has shown that dysregulation of miRNA expression is related to the pathogenesis of various human diseases and cancers. Thus, stragegies involving either restoring the expression of tumor suppressor miRNAs or inhibiting overexpressed oncogenic miRNAs hold potential for targeted cancer therapies. However, delivery of miRNAs to tumor tissues is a challenging task. Recent advances in nanotechnology have enabled successful tumor-targeted delivery of miRNA therapeutics through newly designed nanoparticle-based carrier systems. As a result, miRNA therapeutics have entered human clinical trials with promising results, and they are expected to accelerate the transition of miRNAs from the bench to the bedside in the next decade. Here, we present recent perspectives and the newest developments, describing several engineered natural and synthetic novel miRNA nanocarrier formulations and their key in vivo applications and clinical trials.

Original languageEnglish (US)
Article number3818
Issue number15
StatePublished - Aug 2022


  • cancer
  • miRNA
  • miRNA inhibitors
  • miRNA mimics
  • nanoparticles

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'miRacle of microRNA-Driven Cancer Nanotherapeutics'. Together they form a unique fingerprint.

Cite this